Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

Matthew P. Goetz, Katrin Sangkuhl, Henk Jan Guchelaar, Matthias Schwab, Michael Province, Michelle Whirl-Carrillo, W. Fraser Symmans, Howard L. McLeod, Mark J. Ratain, Hitoshi Zembutsu, Andrea Gaedigk, Ron H. van Schaik, James N. Ingle, Kelly E. Caudle, Teri E. Klein

Research output: Contribution to journalArticle

79 Scopus citations

Abstract

Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.

Original languageEnglish (US)
Pages (from-to)770-777
Number of pages8
JournalClinical pharmacology and therapeutics
Volume103
Issue number5
DOIs
StatePublished - May 2018

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy'. Together they form a unique fingerprint.

  • Cite this

    Goetz, M. P., Sangkuhl, K., Guchelaar, H. J., Schwab, M., Province, M., Whirl-Carrillo, M., Symmans, W. F., McLeod, H. L., Ratain, M. J., Zembutsu, H., Gaedigk, A., van Schaik, R. H., Ingle, J. N., Caudle, K. E., & Klein, T. E. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clinical pharmacology and therapeutics, 103(5), 770-777. https://doi.org/10.1002/cpt.1007